EJNMMI Research最新文献

筛选
英文 中文
Effect of cerebral sinus venous thrombosis and its location on cerebral blood flow: a [15O]water PET study in acute stroke patients compared to healthy volunteers. 脑窦静脉血栓形成及其位置对脑血流的影响:急性脑卒中患者与健康志愿者的[15O]水 PET 研究比较。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-21 DOI: 10.1186/s13550-024-01180-9
Andreas Harloff, Ganna Blazhenets, Johannes Fostitsch, Christoph Strecker, Rick Dersch, Ernst Mayerhofer, Philipp T Meyer
{"title":"Effect of cerebral sinus venous thrombosis and its location on cerebral blood flow: a [<sup>15</sup>O]water PET study in acute stroke patients compared to healthy volunteers.","authors":"Andreas Harloff, Ganna Blazhenets, Johannes Fostitsch, Christoph Strecker, Rick Dersch, Ernst Mayerhofer, Philipp T Meyer","doi":"10.1186/s13550-024-01180-9","DOIUrl":"10.1186/s13550-024-01180-9","url":null,"abstract":"<p><strong>Background: </strong>Symptoms in acute cerebral sinus venous thrombosis (CSVT) are highly variable, ranging from headaches to fatal stroke, and the basis for this high inter-individual variability is poorly understood. The present study aimed to assess whether acute CSVT significantly alters regional cerebral blood flow (CBF), if findings differ from CBF patterns know from large-artery occlusion in stroke, and whether the pattern of CBF alterations depends on clot location. Therefore, we retrospectively analyzed 12 patients with acute CSVT 10.6 ± 4.6 days after symptom onset and ten healthy volunteers who underwent [<sup>15</sup>O]water PET (two scans each, 300 ± 14 MBq [<sup>15</sup>O]water). Static image datasets (15-75 s after injection; normalized to cerebellum) reflecting relative CBF (rCBF) were analyzed using voxel- and region-of-interest-based analysis (AAL3-atlas). We mirrored datasets of patients with left-sided CSVT to harmonize the affected hemisphere.</p><p><strong>Results: </strong>Seven and five patients showed right- and left-sided CSVT, respectively. The superior sagittal sinus (SSS) was involved in 8/12 patients. CSVT patients had extensive rCBF deficits in the voxel-based analysis with accentuation in the right (ipsilateral) frontal cortex and caudate nucleus compared to controls, which were most pronounced in cortical areas in those with involvement of the SSS (8/12), and in subcortical areas in those without involvement of the SSS (4/12; p < 0.05, false discovery rate corrected). ROI-analysis demonstrated significant frontal (p = 0.01) and caudate nucleus (p = 0.008) rCBF deficits driven by patients with and without SSS occlusion, respectively.</p><p><strong>Conclusions: </strong>[<sup>15</sup>O]water PET was able to visualize characteristic patterns of impaired rCBF, which were different from intracranial large-artery occlusion in acute ischemic stroke, and exhibited substantial rCBF alterations depending on the involvement of the SSS. Our findings provide novel insights into the effects of disturbed venous drainage on CBF in acute CSVT, which may aid in understanding the pathophysiology, and guide future therapy of acute CSVT.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"116"},"PeriodicalIF":3.1,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11582296/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142686406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model. 利用基于成像特征的模型预测接受 CAR-T 疗法的 B 细胞淋巴瘤患者的生存期、神经毒性和反应。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-20 DOI: 10.1186/s13550-024-01172-9
Blanca Ferrer-Lores, Alfonso Ortiz-Algarra, Alfonso Picó-Peris, Alejandra Estepa-Fernández, Fuensanta Bellvís-Bataller, Glen J Weiss, Almudena Fuster-Matanzo, Juan Pedro Fernández, Ana Jimenez-Pastor, Rafael Hernani, Ana Saus-Carreres, Ana Benzaquen, Laura Ventura, José Luis Piñana, Ana Belén Teruel, Alicia Serrano-Alcalá, Rosa Dosdá, Pablo Sopena-Novales, Aitana Balaguer-Rosello, Manuel Guerreiro, Jaime Sanz, Luis Martí-Bonmatí, María José Terol, Ángel Alberich-Bayarri
{"title":"Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model.","authors":"Blanca Ferrer-Lores, Alfonso Ortiz-Algarra, Alfonso Picó-Peris, Alejandra Estepa-Fernández, Fuensanta Bellvís-Bataller, Glen J Weiss, Almudena Fuster-Matanzo, Juan Pedro Fernández, Ana Jimenez-Pastor, Rafael Hernani, Ana Saus-Carreres, Ana Benzaquen, Laura Ventura, José Luis Piñana, Ana Belén Teruel, Alicia Serrano-Alcalá, Rosa Dosdá, Pablo Sopena-Novales, Aitana Balaguer-Rosello, Manuel Guerreiro, Jaime Sanz, Luis Martí-Bonmatí, María José Terol, Ángel Alberich-Bayarri","doi":"10.1186/s13550-024-01172-9","DOIUrl":"10.1186/s13550-024-01172-9","url":null,"abstract":"<p><strong>Background: </strong>This multicentre retrospective observational study aims to develop imaging-based prognostic and predictive models for relapsed/refractory (R/R) B-cell lymphoma patients undergoing CAR-T therapy by integrating clinical data and imaging features. Specifically, our aim was to predict 3- and 6-month treatment response, overall survival (OS), progression-free survival (PFS), and the occurrence of the immune effector cell-associated neurotoxicity syndrome (ICANS).</p><p><strong>Results: </strong>Sixty-five patients of R/R B-cell lymphoma treated with CAR-T cells in two centres were included. Pre-infusion [<sup>18</sup>F]FDG PET/CT scans and clinical data were systematically collected, and imaging features, including kurtosis, entropy, maximum diameter, standardized uptake value (SUV) related features (SUV<sub>max</sub>, SUV<sub>mean</sub>, SUV<sub>std</sub>, SUV<sub>median</sub>, SUV<sub>p25</sub>, SUV<sub>p75</sub>), total metabolic tumour volume (MTV<sub>total</sub>), and total lesion glycolysis (TLG<sub>total</sub>), were extracted using the Quibim platform. The median age was 62 (range 21-76) years and the median follow-up for survivors was 10.47 (range 0.20-45.80) months. A logistic regression model accurately predicted neurotoxicity (AUC: 0.830), and Cox proportional-hazards models for CAR-T response at 3 and 6 months demonstrated high accuracy (AUC: 0.754 and 0.818, respectively). Median predicted OS after CAR-T therapy was 4.73 months for high MTV<sub>total</sub> and 37.55 months for low MTV<sub>total</sub>. Median predicted PFS was 2.73 months for high MTV<sub>total</sub> and 11.83 months for low MTV<sub>total</sub>. For all outcomes, predictive models, combining imaging features and clinical variables, showed improved accuracy compared to models using only clinical variables or imaging features alone.</p><p><strong>Conclusion: </strong>This study successfully integrates imaging features and clinical variables to predict outcomes in R/R B-cell lymphoma patients undergoing CAR-T. Notably, the identified MTV<sub>total</sub> cut-off effectively stratifies patients, as evidenced by significant differences in OS and PFS. Additionally, the predictive models for neurotoxicity and CAR-T response show promising accuracy. This comprehensive approach holds promise for risk stratification and personalized treatment strategies which may become a helpful tool for optimizing CAR-T outcomes in R/R lymphoma patients.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"113"},"PeriodicalIF":3.1,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11579271/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quantification of [99mTc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization? [99m锝]锝-HDP 骨 SPECT/CT 定量:能否通过更稳健的归一化改进基于体重的标准化摄取值?
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-19 DOI: 10.1186/s13550-024-01167-6
Damian Tiberiu, Noel Spielhofer, Jakob Heimer, Alexander W Sauter, Cristina Popescu, Daniel Hausmann, Jason L Manser, Karim Eid, Rahel A Kubik-Huch, Irene A Burger
{"title":"Quantification of [<sup>99m</sup>Tc]Tc-HDP bone SPECT/CT: can we improve the body weight based standardized uptake value with a more robust normalization?","authors":"Damian Tiberiu, Noel Spielhofer, Jakob Heimer, Alexander W Sauter, Cristina Popescu, Daniel Hausmann, Jason L Manser, Karim Eid, Rahel A Kubik-Huch, Irene A Burger","doi":"10.1186/s13550-024-01167-6","DOIUrl":"10.1186/s13550-024-01167-6","url":null,"abstract":"<p><strong>Background: </strong>The introduction of quantitative SPECT/CT allows more objective assessments of tracer accumulation in SPECT. However standardized uptake values (SUV) still do not play a big role for orthopedic or oncologic questions. With a more reliable normalization, the use of quantitative measures might also be of use for a more objective assessment of lesions. We retrospectively included patients that received a quantitative [<sup>99m</sup>Tc]-HDP bone SPECT/CT scan of the lumbar spine for 4 body weight (BW) categories. Measurements of bone activity (kBq/cc) and bone density in Hounsfield Units (HU) in a standard volume of interest in the femur, the first and the fifth lumbar vertebra of all patients, without active disease within these regions was made. Correlations between tracer uptake and clinical parameters (BW, height, age, gender) were assessed with a multiple regression and based on the model coefficients, a correction formula was calculated and applied.</p><p><strong>Results: </strong>The strongest correlation between measured activity in L1 and patient parameters was found for BW (r= -0.64, p < 0.001), compared to height (r = -0.28, p = 0.002) and age (r = -0.34, p = 0.001). Furthermore, there was a weak positive correlation between tracer accumulation and bone density (r: 0.35, p < 0.001). Using standard normalization with BW there was a very weak positive correlation between SUV<sub>BW</sub> at L1 and BW with a slight overestimation in heavier subjects (r = 0.15, p = 0.09). The calculated correction based on the multiple regression of activity as dependent variable, and weight, age and bone density as significant predictors resulted in more robust uptake values with non-significant associations to BW, height, age or density. However, there was still a wide interindividual range of values for normalized bone activity.</p><p><strong>Conclusion: </strong>Using an age, bone density and weight-based normalization significantly decreased the interindividual variability of normal uptake on quantitative SPECT/CT compared to the regularly used BW adjusted SUV<sub>BW</sub>. However, a generalized normalization is difficult in the presence of strong patient effects, not attributable to the measured clinical variables.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"111"},"PeriodicalIF":3.1,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First-in-human study of 99mTc-labeled fucoidan, a SPECT tracer targeting P-selectin. 99mTc 标记的褐藻糖胶(一种针对 P 选择素的 SPECT 示踪剂)的首次人体研究。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-19 DOI: 10.1186/s13550-024-01173-8
Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes, Didier Letourneur, Hein J Verberne, Cédric Chauvierre, Mia R Ståhle
{"title":"First-in-human study of <sup>99m</sup>Tc-labeled fucoidan, a SPECT tracer targeting P-selectin.","authors":"Reindert F Oostveen, Kang H Zheng, Yannick Kaiser, Nick S Nurmohamed, Jeffrey Kroon, Tim C de Wit, Edwin Poel, Joel Aerts, Francois Rouzet, Erik S G Stroes, Didier Letourneur, Hein J Verberne, Cédric Chauvierre, Mia R Ståhle","doi":"10.1186/s13550-024-01173-8","DOIUrl":"10.1186/s13550-024-01173-8","url":null,"abstract":"<p><strong>Background: </strong>Activation of endothelial cells and platelets in atherothrombosis is characterized by upregulation of P-selectin. As a consequence, P-selectin represents a potential target for molecular imaging to identify thrombosis at an early stage. Fucoidan is a polysaccharide ligand extracted from brown algae with nanomolar affinity for P-selectin. This first-in-human study evaluated in healthy volunteers the safety, whole-body biodistribution, and dosimetry of <sup>99m</sup>Tc-fucoidan (Good Manufacturing Practices grade). We also investigated whether we could observe binding of <sup>99m</sup>Tc-fucoidan to human thrombi ex vivo and in vivo. In ten healthy volunteers, conjugate whole-body scans were performed up to 24 h following intravenous injection of <sup>99m</sup>Tc-fucoidan (370 MBq). Moreover, <sup>99m</sup>Tc-fucoidan uptake in ex vivo human thrombi (n = 11) was measured by gamma counting. Additionally, three patients with a newly diagnosed deep vein thrombosis (DVT) were subjected to <sup>99m</sup>Tc-fucoidan SPECT/CT imaging.</p><p><strong>Results: </strong><sup>99m</sup>Tc-fucoidan was well tolerated in all participants without any drug-related adverse events. The total-body absorbed dose in males was comparable to females (0.012 ± 0.004 vs. 0.011 ± 0.005 mSv/MBq; p = 0.97). Gamma counting experiments demonstrated binding of tracer to ex vivo human thrombi that was 16% lower after blocking with a natural P-selectin ligand, Sialyl Lewis X. <sup>99m</sup>Tc-fucoidan demonstrated specific uptake at the thrombus site in one out of three scanned patients with DVT.</p><p><strong>Conclusions: </strong><sup>99m</sup>Tc-Fucoidan has a favorable biodistribution and safety profile. <sup>99m</sup>Tc-fucoidan exhibited specific binding to human thrombi in both in vivo and ex vivo settings. Nonetheless, the in vivo results do not support further clinical investigation of <sup>99m</sup>Tc-fucoidan as an imaging modality for DVT. Other clinical implementations of a technetium- 99m-labeled P-selectin tracer should be considered.</p><p><strong>Trial registration: </strong>Clinicaltrials,NCT03422055.Registered 01/15/2018. URL: https://clinicaltrials.gov/study/NCT03422055 Landelijk Trial Register, NL7739. Registered 4/2/2019 . https://onderzoekmetmensen.nl/en/trial/26785.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"112"},"PeriodicalIF":3.1,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11576749/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study. PRRT 剂量参数的演变及对临床实践的潜在影响:前瞻性 II 期 LUMEN 研究数据。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-18 DOI: 10.1186/s13550-024-01163-w
Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, Paulus Kristanto, Wendy Delbart, Bruno Vanderlinden, Zéna Wimana, Alain Hendlisz, Hugo Levillain, Nick Reynaert, Patrick Flamen, Ioannis Karfis
{"title":"Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.","authors":"Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, Paulus Kristanto, Wendy Delbart, Bruno Vanderlinden, Zéna Wimana, Alain Hendlisz, Hugo Levillain, Nick Reynaert, Patrick Flamen, Ioannis Karfis","doi":"10.1186/s13550-024-01163-w","DOIUrl":"10.1186/s13550-024-01163-w","url":null,"abstract":"<p><strong>Background: </strong>Peptide receptor radionuclide therapy (PRRT) with [<sup>177</sup>Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its treatment protocol is currently standardised for all patients, resulting in different patient outcomes. This study investigates the variability of tumours and organs-at-risk (kidneys and red marrow) dosimetric parameters across treatment cycles in patients with pancreatic and intestinal NETs. Data from 37 patients enrolled in a prospective phase II study (LuMEn) were analysed. Treatment consisted of four cycles of [<sup>177</sup>Lu]Lu-DOTA-TATE administered 8-12 weeks apart. Three-time-point SPECT/CT imaging was performed after each treatment cycle, and dosimetry of tumours and organs-at-risk (kidneys and red marrow) was conducted following the medical internal radiation dose formalism. Coefficients of variation (CoV) assessed the variability of absorbed doses, activity concentrations on day 1, and effective half-lives. Linear mixed effect models (SAS software) were used to investigate the evolution of the dosimetric parameters over cycles, discerning between different primary NET types and grades of tumours.</p><p><strong>Results: </strong>There is an important variability in absorbed doses and activity concentrations among patients, particularly in tumours (CoV: ~50%). Tumour absorbed doses and activity concentrations decreased over treatment cycles in pancreatic NETs, although at a limited rate (~-13%/cycle). An opposite trend was observed for the kidneys ( ~ + 8%/cycle). Effective half-lives remained relatively constant across cycles for both organs-at-risk and tumours. The primary NET type significantly influenced effective half-lives in tumours, shorter in pancreatic NETs than intestinal NETs (77 h vs. 107 h, p < 0.0001). No significant effect of the grade was observed on either of the variables investigated.</p><p><strong>Conclusions: </strong>Our study revealed considerable variations in tumour absorbed doses among patients with NETs treated with a standardized protocol. These findings confirm the need for personalized dosimetry approaches in PRRT, considering patient and tumour characteristics.</p><p><strong>Trial registration: </strong>EudraCT Number: 2012-003666-41.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT01842165. Registered 25 April 2013, https://clinicaltrials.gov/ct2/show/NCT01842165 .</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"110"},"PeriodicalIF":3.1,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11574229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142667162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experimental study of early evaluation of radiosensitivity in mouse models of lung cancers using 89Zr-anti-γH2AX-TAT PET imaging. 利用 89Zr-anti-γH2AX-TAT PET 成像对肺癌小鼠模型的放射敏感性进行早期评估的实验研究。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-14 DOI: 10.1186/s13550-024-01178-3
Xiao-Min Li, Jie Gao, Jian-Guo Li, Jian-Bo Song, Si-Jin Li
{"title":"Experimental study of early evaluation of radiosensitivity in mouse models of lung cancers using <sup>89</sup>Zr-anti-γH2AX-TAT PET imaging.","authors":"Xiao-Min Li, Jie Gao, Jian-Guo Li, Jian-Bo Song, Si-Jin Li","doi":"10.1186/s13550-024-01178-3","DOIUrl":"10.1186/s13550-024-01178-3","url":null,"abstract":"<p><strong>Background: </strong>Early evaluation of radiation sensitivity in lung cancer patients can facilitate the transition to personalized treatment strategies. To this end, we assessed the capability of <sup>89</sup>Zr-anti-γH2AX-TAT microPET imaging in determining the radiosensitivity of lung cancer xenograft models. We prepared and conducted quality control on <sup>89</sup>Zr-anti-γH2AX-TAT. The radiosensitivity of human non-small cell lung cancer cells (H460) and adenocarcinoma cells (A549) was analyzed through clonogenic survival experiments. Additionally, the role of γH2AX as a biomarker for radiosensitivity was validated by quantifying γH2AX foci via fluorescence staining. Subsequently, the H460 and A549 xenograft mouse models were subjected to irradiation, followed by <sup>89</sup>Zr-anti-γH2AX-TAT microPET imaging. Concurrently, we performed immunofluorescence staining for γH2AX in tumor tissues to establish a correlation between the uptake of <sup>89</sup>Zr-anti-γH2AX-TAT and γH2AX expression.</p><p><strong>Results: </strong>The surviving fraction 2 Gy (SF2) values of H460 and A549 indicating that A549 adenocarcinoma has higher radiosensitivity. The cell immunofluorescence experiment showed that the repair of γH2AX foci in H460 cells after irradiation was significantly higher than that in A549 cells, which also confirmed that A549 has higher radiosensitivity. The microPET imaging results showed the uptake of <sup>89</sup>Zr-anti-γH2AX-TAT in the tumor of the A549 models after radiotherapy was higher than H460 models. The immunofluorescence staining of tumor tissue confirmed that the expression level of γH2AX was higher and the correlation with microPET imaging uptake was good.</p><p><strong>Conclusion: </strong><sup>89</sup>Zr-anti-γH2AX-TAT allows PET imaging of radiosensitivity in lung cancer xenograft models, and is expected to become an early evaluation method for lung cancer radiosensitivity.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"108"},"PeriodicalIF":3.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary mesenchymal tumors of the prostate:18F FDG PET/CT findings. 前列腺原发性间质瘤:18F FDG PET/CT 发现。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-14 DOI: 10.1186/s13550-024-01177-4
Zihao Tao, Yongkang Qiu, Zhao Chen, Wenpeng Huang, Lele Song, Aixiang Wang, Xuesong Li, Lei Kang
{"title":"Primary mesenchymal tumors of the prostate:<sup>18</sup>F FDG PET/CT findings.","authors":"Zihao Tao, Yongkang Qiu, Zhao Chen, Wenpeng Huang, Lele Song, Aixiang Wang, Xuesong Li, Lei Kang","doi":"10.1186/s13550-024-01177-4","DOIUrl":"10.1186/s13550-024-01177-4","url":null,"abstract":"<p><strong>Background: </strong>Primary mesenchymal tumors of the prostate are very rare, and there is no systematic report on fluorine-18-fluorodeoxyglucose positron emission tomography (<sup>18</sup>F-FDG PET/CT). The aim of this research was to characterize mesenchymal tumors of the prostate on <sup>18</sup>F-FDG PET/CT.</p><p><strong>Results: </strong>We included 13 patients with pathologically confirmed mesenchymal neoplasms of the prostate. The location, size, maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total glycolysis of the lesion (TLG), pathologic findings, and available imaging study of the tumors were reviewed. Of the 13 patients (median age, 38 years; ranged from 13 to 74 years), the mean size of the tumors was 8.8 cm in diameter ranged from 5 to 16.1 cm. SUVmax ranged from 3.1 to 17.6 (mean 9.5), MTV ranged from 4.9 to 398 cm<sup>3</sup> (mean 109 cm<sup>3</sup>) and TLG ranged from 21.3 to 1216 g (mean 96 g). The seminal vesicles, rectum, and bladder are the most commonly affected sites of invasion, while metastasis typically occurs in the bones, lungs, and lymph nodes.</p><p><strong>Conclusions: </strong>Mesenchymal tumors of the prostate revealed large sizes and high SUVmax, MTV and TLG levels on <sup>18</sup>F-FDG PET/CT. <sup>18</sup>F-FDG PET/CT may be useful for accurate diagnosis, staging, and restaging, which plays an important role in the management of subsequent plans.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"109"},"PeriodicalIF":3.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Light up heart-type fatty acid binding protein (FABP3) with a novel fluorine-18 labelled selective FABP3 ligand. 用新型氟-18 标记的选择性 FABP3 配体点亮心脏型脂肪酸结合蛋白 (FABP3)。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-14 DOI: 10.1186/s13550-024-01175-6
Jun Toyohara, Taichi Komoda, Tetsuro Tago, Masahiko Ito, Hiroshi Yoshino
{"title":"Light up heart-type fatty acid binding protein (FABP3) with a novel fluorine-18 labelled selective FABP3 ligand.","authors":"Jun Toyohara, Taichi Komoda, Tetsuro Tago, Masahiko Ito, Hiroshi Yoshino","doi":"10.1186/s13550-024-01175-6","DOIUrl":"10.1186/s13550-024-01175-6","url":null,"abstract":"<p><strong>Background: </strong>Heart-type fatty acid binding proteins (FABP3) constitute a family of lipid chaperone proteins. They are found in the cytosol and enhance cellular fatty acid solubilisation, transport, and metabolism. FABP3 is highly expressed in the myocardium and is released from myocytes during myocardial damage. As FABP3 content in the myocardium is closely related to the metabolic state of fatty acids, we hypothesised that targeting of FABP3 with a radiolabelled small organic compound would visualise myocardium.</p><p><strong>Results: </strong>The selective FABP3 inhibitor, 4-(4-fluoro-2-(1-phenyl-5-(2-(trifluoromethyl)phenyl)-1H-pyrazol-3-yl)phenoxy)butanoic acid (LUF), was radiolabelled via a two-step reaction comprising copper-mediated <sup>18</sup>F-fluorination of an arylboronic precursor followed by alkaline hydrolysis of the ethoxy protecting group. [<sup>18</sup>F]LUF was successfully synthesised by automated synthesiser with sufficient activity yields (14.0 ± 1.8 GBq) and high quality (molar activity, > 250 GBq/µmol and radiochemical purity, > 99.6%). Biological assessment of [<sup>18</sup>F]LUF as an in vivo myocardial imaging agent included evaluations of biodistribution, metabolite analysis, and positron emission tomography (PET) imaging of small animals. [<sup>18</sup>F]LUF clearly visualised the myocardium with high contrast against background tissues such as the lung and liver. [<sup>18</sup>F]LUF also showed a high absolute myocardial uptake equivalent to that of the promising myocardial perfusion tracer [<sup>18</sup>F]flurpiridaz and excellent metabolic stability in the body. These properties are ideal for stable and noise-less imaging of the heart. PET imaging of rat surgical permanent myocardial infarction (MI) and experimental autoimmune myocarditis (EAM) was also performed. [<sup>18</sup>F]LUF successfully visualised lesions of permanent MI and EAM.</p><p><strong>Conclusion: </strong>Our results showed for the first time that the <sup>18</sup>F-labelled FABP3 selective small organic compound clearly visualised myocardium with good quality. To determine the clinical utility of [<sup>18</sup>F]LUF for cardiovascular disease in clinical practice, it will be necessary to evaluate a greater variety of cardiovascular disease models and elucidate the accumulation mechanism, particularly in relation to fatty acid metabolism in the myocardium.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"107"},"PeriodicalIF":3.1,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11564661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Distinguishing lymphoma from benign lymph node diseases in fever of unknown origin using PET/CT radiomics. 利用 PET/CT 放射线组学区分不明原因发热中的淋巴瘤和良性淋巴结疾病。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-13 DOI: 10.1186/s13550-024-01171-w
Xinchao Zhang, Fenglian Jing, Yujing Hu, Congna Tian, Jianyang Zhang, Shuheng Li, Qiang Wei, Kang Li, Lu Zheng, Jiale Liu, Jingjie Zhang, Yanzhu Bian
{"title":"Distinguishing lymphoma from benign lymph node diseases in fever of unknown origin using PET/CT radiomics.","authors":"Xinchao Zhang, Fenglian Jing, Yujing Hu, Congna Tian, Jianyang Zhang, Shuheng Li, Qiang Wei, Kang Li, Lu Zheng, Jiale Liu, Jingjie Zhang, Yanzhu Bian","doi":"10.1186/s13550-024-01171-w","DOIUrl":"10.1186/s13550-024-01171-w","url":null,"abstract":"<p><strong>Background: </strong>A considerable portion of patients with fever of unknown origin (FUO) present concomitant lymphadenopathy. Diseases within the spectrum of FUO accompanied by lymphadenopathy include lymphoma, infections, and rheumatic diseases. Particularly, lymphoma has emerged as the most prevalent etiology of FUO with associated lymphadenopathy. Distinguishing between benign and malignant lymph node lesions is a major challenge for physicians and an urgent clinical concern for patients. However, conventional imaging techniques, including PET/CT, often have difficulty accurately distinguishing between malignant and benign lymph node lesions. This study utilizes PET/CT radiomics to differentiate between lymphoma and benign lymph node lesions in patients with FUO, aiming to improve diagnostic accuracy.</p><p><strong>Results: </strong>Data were collected from 204 patients who underwent <sup>18</sup>F-FDG PET/CT examinations for FUO, including 114 lymphoma patients and 90 patients with benign lymph node lesions. Patients were randomly divided into training and testing groups at a ratio of 7:3. A total of 15 effective features were obtained by the least absolute shrinkage and selection operator (LASSO) algorithm. Machine learning models were constructed using logistic regression (LR), support vector machine (SVM), random forest (RF), and k-nearest neighbors (KNN) algorithms. In the training group, the area under the curve (AUC) values for predicting lymphoma and benign cases by LR, SVM, RF, and KNN models were 0.936, 0.930, 0.998, and 0.938, respectively. There were statistically significant differences in AUC between the RF and other models (all P < 0.001). In the testing group, the AUC values for the four models were 0.860, 0.866, 0.915, and 0.891, respectively, with no statistically significant differences observed among them (all P > 0.05). The decision curve analysis (DCA) curves of the RF model outperformed those of the other three models in both the training and testing groups.</p><p><strong>Conclusions: </strong>PET/CT radiomics demonstrated promising performance in discriminating lymphoma from benign lymph node lesions in patients with FUO, with the RF model showing the best performance.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"106"},"PeriodicalIF":3.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561199/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours. 68[Ga]Ga-DOTA-TATE PET/CT 体积参数在评估分化良好的神经内分泌肿瘤患者对长效体生长激素类似物治疗反应中的预测价值。
IF 3.1 3区 医学
EJNMMI Research Pub Date : 2024-11-13 DOI: 10.1186/s13550-024-01169-4
Karolina Morawiec-Sławek, Marta Opalińska, Wioletta Lenda-Tracz, Katarzyna Sitarz, Anna Kurzyńska, Agnieszka Stefańska, Magdalena Kolasa, Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk
{"title":"Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours.","authors":"Karolina Morawiec-Sławek, Marta Opalińska, Wioletta Lenda-Tracz, Katarzyna Sitarz, Anna Kurzyńska, Agnieszka Stefańska, Magdalena Kolasa, Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk","doi":"10.1186/s13550-024-01169-4","DOIUrl":"10.1186/s13550-024-01169-4","url":null,"abstract":"<p><strong>Background: </strong>Over the past decade, numerous treatment options have emerged for patients with locally advanced and metastatic neuroendocrine tumours (NETs). Nevertheless, the optimal timing of treatment interventions remains uncertain, given the highly variable disease course observed in these patients, even when patients have the same tumour stage and grade. The aim of the study was to evaluate the predictive role of standardized uptake values (SUVs) and volumetric parameters obtained from pretreatment [68Ga]Ga-DOTA-TATE for response to SSA therapy in patients with NET. In this retrospective study, we included 42 patients (21 women, 21 men; age range: 46-84 years) with histologically confirmed, metastatic, NET (G1 13, G2 28 cases); median Ki-67 index 5%, range 1-16) who received long acting SSA as a first line treatment and underwent [68Ga]Ga-DOTA-TATE PET/CT before SSA treatment. For all [68Ga]Ga-DOTA-TATE avid lesion SUVmax, SUVmean, somatostatin receptor expression tumour volume (STV), total lesion somatostatin receptor expression (TLD, STV multiplied by SUV mean) and Tmean/Smean (SUVmean of tumours/metastases divided by SUVmean of normal spleen) were measured. Finally, the sum of STV (total STV, TSTV) and TLD (total TLD, TTLD) was calculated for each patient and used in the analysis.</p><p><strong>Results: </strong>During the study period, 14 patients had stable disease (33.3%) and 28 patients experienced progression (66.7%), among whom 12 patients died. The median progression-free survival (PFS) and overall survival (OS) were 26.5 and 46.5 months, respectively. In the univariate and multivariate analysis, in the whole population study, Tmean/Smean ratio (HR 1.88, 95% CI 1.06-3.35, p = 0.03), Ki-67 index (HR 1.14, CI 1.03-1.26, p = 0.01) and pre-treatment chromogranin A serum concentration (HR 1.01, CI 1.0-1.03, p = 0.01) were significantly associated with PFS. Among patients with small intestinal NETs, TSTV (< 125.85 cm<sup>3</sup> vs. ≥ 125.85 cm<sup>3</sup>, p = 0.023) and TTLD (< 4168.95 vs. ≥ 4168.95, p = 0.026) were significantly associated with PFS in the univariate analyses. No significant correlation was found between measured volumetric parameters and OS.</p><p><strong>Conclusion: </strong>Volumetric parameters of pretreatment 68[Ga]Ga-DOTA-TATE PET/CT may be useful in prediction of the response to SSA (used in monotherapy as a first-line therapy) in patients with NET.</p>","PeriodicalId":11611,"journal":{"name":"EJNMMI Research","volume":"14 1","pages":"105"},"PeriodicalIF":3.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信